K-562細(xì)胞

細(xì)胞形態(tài)： **樣

數(shù)量： 大量

是否是腫瘤細(xì)胞： 0

物種來源： 人

運(yùn)輸方式： 凍存運(yùn)輸

生長狀態(tài)： 懸浮生長

器官來源： 骨髓

年限： 53 years

ATCC Number： CCL-243?

相關(guān)**： 其他**

Designations: K-562

Depositors: HT Holden

Biosafety Level: 1

Shipped: frozen

K-562細(xì)胞Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens

Morphology: lymphoblast

Source: Organ: bone marrow

Disease: chronic myelogenous leukemia (CML)

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: transfection host

Tumorigenic: Yes

Antigen Expression: CD7 (25%)

DNA Profile (STR): Amelogenin: X

CSF1PO: 9,10

D13S317: 8

D16S539: 11,12

D5S818: 11,12

D7S820: 9,11

THO1: 9.3

TPOX: 8,9

vWA: 16

Cytogenetic Analysis: The stemline chromosome number is triploid with the 2S component occurring at 4.2%. Fifteen markers (M1 and M(15)) occurred in nearly all S metaphases. Spontaneous non-specific dicentrics occurred, but rarely. Unstable markers were also rarely seen. The X was disomic, and N9 was nullisomic.

K-562細(xì)胞Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 2

Me-2, 0

PGM1, 0

PGM3, 1

Age: 53 years

Gender: female

Comments: The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.

The cell population has been characterized as highly undifferentiated and of the granulocytic series.

Studies conducted by Anderson, et al., on the surface membrane properties led to the conclusion that the K-562 was a human erythroleukemia line.

The K-562 cell line has attained widespread use as a highly sensitive in vitro target for the natural killer assay.

See Pross, et al. for a detailed analysis of the in vitro assay of NK cells including the mathematics of quantitation of NK cell activity.

K-562 blasts are multipotential, hematopoietic malignant cells that spontaneously differentiate into recognizable progenitors of the erythrocytic, granulocytic and monocytic series.

K-562細(xì)胞The effect of inducers on sublines derived from the original K-562 cell line have been reviewed by Koeffler and Golde.

Cultures from the ATCC stock have been shown to exhibit this sensitivity for assessing human natural killer activity.

Karyological studies on various K-562 sublines have been classified into three groups (A,B,C) by Dimery, et al.

The strain obtained by the ATCC most closely resembles the B population. Occurrence of the Philadelphia chromosome, however, was of much lower frequency; none detected in 15 metaphases examined.

The line is EBNA negative.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by the addition or replacement of fresh medium. Start new cultures at 1 X 10 exp5 viable cells/ml. Subculture at 1 X 10 exp6 cells/ml.

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor temperature

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005

recommended serum:ATCC 30-2020

purified DNA:ATCC CCL-243D

purified RNA:ATCC CCL-243R

References: 867: K-562細(xì)胞Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 56: 344-350, 1980. PubMed: 6996765

1101: Ortaldo JR, et al. Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J. Natl. Cancer Inst. 59: 77-82, 1977. PubMed: 69036

22609: Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975. PubMed: 163658

26059: Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res. 3: 363-370, 1979. PubMed: 95026

26060: Andersson LC, et al. K562--a human erythroleukemic cell line. Int. J. Cancer 23: 143-147, 1979. PubMed: 367973

26061: Lozzio BB, et al. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 166: 546-550, 1981. PubMed: 7194480

26063: Dimery IW, et al. Variation amongst K562 cell cultures. Exp. Hematol. 11: 601-610, 1983. PubMed: 6576909

32357: Chan YJ, et al. Two distinct upstream regulatory domains containing multicopy cellular transcription factor binding sites provide basal repression and inducible enhancer characteristics to the immediate-early IES (US3) promoter from human cytomegalovirus. J. Virol. 70: 5312-5328, 1996. PubMed: 8764042

32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128

32446: Gan W, Rhoads RE. Internal initiation of translation directed by the 5'-untranslated region of the mRNA for eIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation. J. Biol. Chem. 271: 623-626, 1996. PubMed: 8557663

32561: Tiffany HL, et al. Enhanced expression of the eosinophil-derived neurotoin ribonuclease (RNS2) gene requires interaction between the promoter and intron. J. Biol. Chem. 271: 12387-12393, 1996. PubMed: 8647842

32704: Chan YJ, et al. K-562細(xì)胞Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus. J. Virol. 70: 8590-8605, 1996. PubMed: 8970984

33044: Nauseel WM, et al. Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. J. Biol. Chem. 271: 9546-9549, 1996. PubMed: 8621627

33174: Grune T, et al. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J. Biol. Chem. 271: 15504-15509, 1996. PubMed: 8663134

48829: Jondal M, Pross H. Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int. J. Cancer 15: 596-605, 1975. PubMed: 806545

48830: West WH, et al. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J. Immunol. 118: 355-361, 1977. PubMed: 299761

48833: Pross HF, et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J. Clin. Immunol. 1: 51-63, 1981. PubMed: 7334070

61237: Chen TR. Modal karyotype of human leukemia cell line, K562 (ATCC CCL 243). Cancer Genet. Cytogenet. 17: 55-60, 1985. PubMed: 3857109

61327: Wu SQ, et al. Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-56. Leukemia 9: 858-862, 1995. PubMed: 7769849